Skip to main content
Fig. 4 | Journal of Inflammation

Fig. 4

From: The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets

Fig. 4

Impact of fetal calf serum (FCS) content on the effects of high concentrations of WIN55212-2 mesylate (WIN, 10−6M to 10−5M)) on TNF-induced IL-6 (a), IL-8 (b) and MMP-3 (c) production in RA and OA synovial fibroblasts. Cytokine/MMP-3 production was determined under hypoxic (1 % O2) conditions. ***p < 0.001, **p < 0.01, *p < 0.05 for comparisons vs WIN/TNF with 0 % FCS. The general linear model with Bonferroni correction was used for all comparisons. All data are given as mean ± sem

Back to article page